• electroCore reported publication in JAMA Network Open of a cluster randomized clinical trial evaluating its Quell wearable nerve-stimulation device as an add-on to outpatient physical therapy for fibromyalgia, with results already presented in the journal article.
• Patients receiving Quell alongside physical therapy saw greater improvement in pain during movement than those receiving physical therapy alone, with benefits emerging early and holding for up to six months.
• Trial enrollment included 384 participants, split between Quell-plus-therapy and therapy-only groups.
• Surveyed users largely described Quell as helpful, with more than half reporting daily use later in follow-up.
• Management framed fibromyalgia as a sizable addressable market, positioning Quell as a non-drug, FDA-cleared option for the condition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130800PRIMZONEFULLFEED9718752) on May 13, 2026, and is solely responsible for the information contained therein.